CA2718538A1 - Quinoline derivatives as axl kinase inhibitors - Google Patents
Quinoline derivatives as axl kinase inhibitors Download PDFInfo
- Publication number
- CA2718538A1 CA2718538A1 CA2718538A CA2718538A CA2718538A1 CA 2718538 A1 CA2718538 A1 CA 2718538A1 CA 2718538 A CA2718538 A CA 2718538A CA 2718538 A CA2718538 A CA 2718538A CA 2718538 A1 CA2718538 A1 CA 2718538A1
- Authority
- CA
- Canada
- Prior art keywords
- yloxy
- phenyl
- quinolin
- fluoro
- benzenesulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4539808P | 2008-04-16 | 2008-04-16 | |
| US61/045,398 | 2008-04-16 | ||
| PCT/EP2009/002798 WO2009127417A1 (en) | 2008-04-16 | 2009-04-16 | Quinoline derivatives as axl kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2718538A1 true CA2718538A1 (en) | 2009-10-22 |
Family
ID=40999731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2718538A Abandoned CA2718538A1 (en) | 2008-04-16 | 2009-04-16 | Quinoline derivatives as axl kinase inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9206130B2 (enExample) |
| EP (1) | EP2262772B8 (enExample) |
| JP (1) | JP5746015B2 (enExample) |
| KR (1) | KR101325237B1 (enExample) |
| CN (1) | CN102131783A (enExample) |
| AU (1) | AU2009237938A1 (enExample) |
| CA (1) | CA2718538A1 (enExample) |
| ES (1) | ES2391373T3 (enExample) |
| IL (1) | IL208103A (enExample) |
| MX (1) | MX2010011224A (enExample) |
| RU (1) | RU2010146474A (enExample) |
| WO (1) | WO2009127417A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2311809A1 (en) * | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
| EP2423208A1 (en) * | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
| ITRM20100537A1 (it) | 2010-10-12 | 2012-04-12 | Consiglio Nazionale Ricerche | Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia |
| EA023521B1 (ru) * | 2011-11-14 | 2016-06-30 | Сефалон, Инк. | ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ |
| SG11201404505PA (en) | 2012-01-31 | 2014-10-30 | Daiichi Sankyo Co Ltd | Pyridone derivative |
| WO2014018535A1 (en) | 2012-07-25 | 2014-01-30 | Salk Institute For Biological Studies | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine |
| TWI649308B (zh) | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | 喹啉衍生物 |
| AU2014353006B2 (en) | 2013-11-20 | 2019-04-04 | Signalchem Life Sciences Corp. | Quinazoline derivatives as TAM family kinase inhibitors |
| CA2922542A1 (en) | 2013-11-22 | 2015-05-28 | University Of Kentucky Research Foundation | Arylquinoline and analog compounds and use thereof to treat cancer |
| JP6496731B2 (ja) | 2013-11-27 | 2019-04-03 | シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体 |
| TWI723572B (zh) | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
| WO2016104617A1 (ja) * | 2014-12-25 | 2016-06-30 | 小野薬品工業株式会社 | キノリン誘導体 |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
| WO2017035366A1 (en) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
| ES2896079T3 (es) | 2016-02-26 | 2022-02-23 | Ono Pharmaceutical Co | Fármaco para la terapia del cáncer, caracterizado por la administración de la combinación entre un inhibidor de Axl y un inhibidor del punto de control inmunitario |
| TWI828027B (zh) | 2016-03-28 | 2024-01-01 | 美商英塞特公司 | 作為tam抑制劑之吡咯并三嗪化合物 |
| CN108250200A (zh) * | 2016-12-28 | 2018-07-06 | 中国科学院上海药物研究所 | 一种具有Axl抑制活性的化合物及其制备和应用 |
| KR102571911B1 (ko) | 2017-01-26 | 2023-08-28 | 오노 야꾸힝 고교 가부시키가이샤 | 퀴놀린 유도체의 에탄술폰산염 |
| EP3673907A4 (en) | 2017-08-23 | 2020-08-19 | ONO Pharmaceutical Co., Ltd. | CANCER TREATMENT PHARMACEUTICAL INCLUDING AX1 INHIBITOR AS AN EFFECTIVE INGREDIENT |
| AU2018325445A1 (en) * | 2017-08-31 | 2020-03-19 | Abbvie Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitors and uses thereof |
| US10633387B2 (en) | 2017-09-27 | 2020-04-28 | Incyte Corporation | Salts of TAM inhibitors |
| US11826363B2 (en) | 2017-10-13 | 2023-11-28 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient |
| ES3031110T3 (en) | 2018-06-29 | 2025-07-04 | Incyte Corp | Formulations of an axl/mer inhibitor |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| PH12022552347A1 (en) | 2020-03-06 | 2024-01-29 | Incyte Corp | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
| US20230295114A1 (en) * | 2020-05-08 | 2023-09-21 | Georgiamune Llc | Akt3 modulators |
| JP2022104746A (ja) * | 2020-12-29 | 2022-07-11 | 国立研究開発法人国立がん研究センター | 抗がん剤 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| IL144461A0 (en) * | 1999-01-22 | 2002-05-23 | Kirin Brewery | Quinoline and quinazoline derivatives and pharmaceutical compositions containing them |
| US7041691B1 (en) * | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| WO2004039782A1 (ja) * | 2002-10-29 | 2004-05-13 | Kirin Beer Kabushiki Kaisha | Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
| EP2210607B1 (en) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| GB0509227D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| US20100234371A1 (en) * | 2005-08-22 | 2010-09-16 | Frank Himmelsbach | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof |
| US20110053931A1 (en) * | 2006-06-08 | 2011-03-03 | John Gaudino | Quinoline compounds and methods of use |
| WO2008076415A1 (en) * | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
-
2009
- 2009-04-16 JP JP2011504377A patent/JP5746015B2/ja active Active
- 2009-04-16 AU AU2009237938A patent/AU2009237938A1/en not_active Abandoned
- 2009-04-16 RU RU2010146474/04A patent/RU2010146474A/ru not_active Application Discontinuation
- 2009-04-16 WO PCT/EP2009/002798 patent/WO2009127417A1/en not_active Ceased
- 2009-04-16 CN CN2009801129869A patent/CN102131783A/zh active Pending
- 2009-04-16 MX MX2010011224A patent/MX2010011224A/es not_active Application Discontinuation
- 2009-04-16 EP EP09731679A patent/EP2262772B8/en active Active
- 2009-04-16 US US12/933,070 patent/US9206130B2/en active Active
- 2009-04-16 KR KR1020107023097A patent/KR101325237B1/ko active Active
- 2009-04-16 CA CA2718538A patent/CA2718538A1/en not_active Abandoned
- 2009-04-16 ES ES09731679T patent/ES2391373T3/es active Active
-
2010
- 2010-09-13 IL IL208103A patent/IL208103A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011517689A (ja) | 2011-06-16 |
| AU2009237938A1 (en) | 2009-10-22 |
| ES2391373T3 (es) | 2012-11-23 |
| EP2262772A1 (en) | 2010-12-22 |
| KR20100132038A (ko) | 2010-12-16 |
| MX2010011224A (es) | 2011-02-25 |
| US9206130B2 (en) | 2015-12-08 |
| IL208103A (en) | 2015-08-31 |
| US20110092503A1 (en) | 2011-04-21 |
| RU2010146474A (ru) | 2012-05-27 |
| CN102131783A (zh) | 2011-07-20 |
| EP2262772B1 (en) | 2012-07-18 |
| EP2262772B8 (en) | 2013-03-13 |
| WO2009127417A1 (en) | 2009-10-22 |
| IL208103A0 (en) | 2010-12-30 |
| JP5746015B2 (ja) | 2015-07-08 |
| KR101325237B1 (ko) | 2013-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2262772B1 (en) | Quinoline derivatives as axl kinase inhibitors | |
| EP1415987B1 (en) | Nitrogenous aromatic ring compounds as anti cancer agents | |
| ES2868355T3 (es) | Inhibidores del bromodominio | |
| TWI473792B (zh) | New quinoline compounds and their use | |
| CA2909310A1 (en) | Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways | |
| CN107098846B (zh) | N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途 | |
| WO2018145621A1 (zh) | 喹啉类化合物、其制备方法及其医药用途 | |
| WO2015188747A1 (zh) | 作为egfr抑制剂的苯基取代的三嗪类化合物及其应用 | |
| CN107056755B (zh) | 五元杂环酰胺类wnt通路抑制剂 | |
| WO2013013614A1 (zh) | 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用 | |
| CN106478606B (zh) | N-取代吲哚类衍生物及其应用 | |
| CN106967004B (zh) | 含脲基的ido1和ido2双重抑制剂、其制法及其医药用途 | |
| WO2017005137A1 (zh) | 喹唑啉类化合物、其中间体、制备方法、药物组合物和应用 | |
| CN113880772B (zh) | 一类cdk激酶抑制剂及其应用 | |
| CA2603125A1 (en) | Thienopyridine derivative, quinoline derivatives,and quinazoline derivatives, having c-met autophosphorylation inhibiting activity | |
| ES2334708T3 (es) | (3,4-dihidro-quinazolin-2-il)-(2-ariloxi-etil)-aminas que tienen una actividad sobre el receptor 5-ht. | |
| BRPI0812816B1 (pt) | Compostos derivados de sulfonil-quinolina, ligantes com preferência para subtipo de receptor mglur1 e mglur5, processos para a preparação dos referidos compostos, formulação farmacêutica compreendedo os referidos compostos e uso dos mesmos | |
| WO2023061051A1 (zh) | 一种磺酰胺类usp8抑制剂及其应用 | |
| TW201934547A (zh) | 一種嘧啶類化合物、其製備方法及其醫藥用途 | |
| CN102558144A (zh) | 一种芳基脲衍生物 | |
| HK1156952A (en) | Quinoline derivatives as axl kinase inhibitors | |
| WO2015043487A1 (zh) | 喹唑啉类化合物及其制备方法与应用 | |
| CN104177312B (zh) | 一种含硒化合物及其医药用途 | |
| CN105263926B (zh) | 苯并噻吩化合物 | |
| CN117343046A (zh) | 一种新型3-氧代-4-取代芳基-3,4-二氢吡嗪-2-甲酰胺类化合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20130416 |